Thus, IL-6 blockade not only has a direct effect on neoplastic cells, and the hallmarks of cancer, but also reeducates the TME towards an antitumor phenotype by altering the proportion of anti-tumor immune cells, making IL-6 an actionable target to prevent tumor progression [Caetano et al., 2016]. The gene discussed is IL6; the disease is cancer.